S100A16-induced adipogenesis is associated with up-regulation of 11 β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

被引:7
|
作者
Zhang, Rihua [1 ]
Kan, Jing Bao [1 ]
Lu, Shan [1 ]
Tong, Pei [1 ]
Yang, Jie [1 ]
Xi, Ling [1 ]
Liang, Xiubing [2 ]
Su, Dongming [2 ]
Li, Dong [3 ]
Liu, Yun [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Geratol, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Ctr Metab Dis Res, Nanjing 210029, Jiangsu, Peoples R China
[3] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Orthoped, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
11-BETA-HYDROXYSTEROID DEHYDROGENASES; INSULIN-RESISTANCE; BINDING PROTEIN; S100A16; OBESITY; DIFFERENTIATION; EXPRESSION; CORTISOL;
D O I
10.1042/BSR20182042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The steadily increasing epidemic of obesity continues at alarming rates, is an important public health problem, and expression changes of S100A16 and 11 beta-hydroxysteroid dehydrogenase type 1(11 beta-HSD1) is attributable to the adipocyte differentiation. In our previous study, we found that 11 beta-HSD1 protein expression increased in S100A16-overexpressed 3T3-L1 cell model. In order to further investigate the relationship between S100A16 and 11 beta-HSD1, and the molecular mechanisms of S100A16-induced adipogenesis, we constructed S100A16 transgenic and knockout mouse, and S100A16-overexpressed 3T3-L1 preadipocyte cell. Using S100A16 transgenic (S100A16(Tg/+)) mice fed with normal fat diet (NFD) and high fat diet (HFD) diet model, we evaluated the effect of S100A16 on adipogenesis, expression of 11 beta-HSD1, and RNA sequencing and quantification of gene expression. Using the 3T3-L1 cell model, we examined the effect of S100A16 and 11 beta-HSD1 on pre-adipocyte differentiation, and cell signaling events of 11 beta-HSD1 overexpression induced by S100A16. We found that when compared with C57BL/6 mice, overexpression of S100A16 under the condition of HFD increased lipid content in WAT and fat infiltration in hepatocytes, 11 beta-HSD1 protein expression increased along with S100A16. Elevated S100A16 and 11 beta-HSD1 expression promoted adipogenesis in 3T3-L1 cells. Overexpression of S100A16 inhibited the degradation of 11 beta-HSD1. We conclude that S100A16-induced adipogenesis is associated with up-regulation of 11 beta-HSD1.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] 11β-hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension
    Campino, Carmen
    Carvajal, Cristian A.
    Cornejo, Javiera
    San Martin, Betty
    Olivieri, Oliviero
    Guidi, Giancesare
    Faccini, Giovanni
    Pasini, Francesco
    Sateler, Javiera
    Baudrand, Rene
    Mosso, Lorena
    Owen, Gareth I.
    Kalergis, Alexis M.
    Padilla, Oslando
    Fardella, Carlos E.
    ENDOCRINE, 2010, 37 (01) : 106 - 114
  • [22] 11β-hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension
    Carmen Campino
    Cristian A. Carvajal
    Javiera Cornejo
    Betty San Martín
    Oliviero Olivieri
    Giancesare Guidi
    Giovanni Faccini
    Francesco Pasini
    Javiera Sateler
    Rene Baudrand
    Lorena Mosso
    Gareth I. Owen
    Alexis M. Kalergis
    Oslando Padilla
    Carlos E. Fardella
    Endocrine, 2010, 37 : 106 - 114
  • [23] Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor
    Gibbs, John P.
    Emery, Maurice G.
    McCaffery, Ian
    Smith, Brian
    Gibbs, Megan A.
    Akrami, Anna
    Rossi, John
    Paweletz, Katherine
    Gastonguay, Marc R.
    Bautista, Edgar
    Wang, Minghan
    Perfetti, Riccardo
    Daniels, Oranee
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (06): : 830 - 841
  • [24] 17β-Hydroxysteroid Dehydrogenase 3 (17β-HSD3), a Regulator of 11β-Hydroxysteroid Dehydrogenase 1 (11β-HSD1) Activity in Rat Leydig Cell.
    Latif, S. A.
    Ge, R.
    Sottas, C. M.
    Shen, M.
    Morris, D. J.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [25] Modulation of 11β-hydroxysteroid dehydrogenase (11βHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11βHSD1 inhibitor
    Courtney, Rachel
    Stewart, Paul M.
    Toh, Melvin
    Ndongo, Marie-Noella
    Calle, Roberto A.
    Hirshberg, Boaz
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02): : 550 - 556
  • [26] Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders
    Yoon, David S.
    Wu, Shung C.
    Seethala, Ramakrishna
    Golla, Rajasree
    Nayeem, Akbar
    Everlof, John G.
    Gordon, David A.
    Hamann, Lawrence G.
    Robl, Jeffrey A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (21) : 5045 - 5049
  • [27] Regulation of Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) by CCAAT/Enhancer-Binding Protein (C/EBP) β Isoforms, LIP and LAP
    Esteves, Cristina L.
    Kelly, Val
    Begay, Valerie
    Man, Tak Y.
    Morton, Nicholas M.
    Leutz, Achim
    Seckl, Jonathan R.
    Chapman, Karen E.
    PLOS ONE, 2012, 7 (05):
  • [28] 11β-hydroxysteroid dehydrogenase type 1 (11-HSD-1) activities in patients with hypopituitarism
    Kobayashi, Y
    Tagawa, N
    Ikariko, N
    Imamura, T
    Higashide, T
    Mori, H
    Inada, H
    Yamano, T
    CLINICAL CHEMISTRY, 2005, 51 : A226 - A226
  • [29] Calcitriol regulation of 11-β hydroxysteroid dehydrogenase 1 (11-β-HSD1) and angiotensin II receptor 1 (AT1) expression in human adipocytes
    Morris, KL
    Miller, SL
    Zemel, MB
    FASEB JOURNAL, 2004, 18 (05): : A878 - A878
  • [30] Oxysterols attenuate the stimulatory effects of TNFα on 11 hydroxysteroid dehydrogenase type 1 (11βHSD1) activity in human adipose stromal cells
    Khalil, W
    Lee, K
    Lim, H
    Smith, N
    Richards, R
    Yang, K
    Killinger, D
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, : 515 - 521